CDEK
← All drugs Report issue

veliparib

Small moleculeexperimental

Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials. — Wikipedia

Clinical trial activity

103 trials · 51 clinical orgs · 0 marketing orgs

Phase 1
62
Phase 2
49
Phase 3
6
Phase 4
0

Earliest trial started Jun 1, 2006 (NCT00387608)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1
Mol. weight
244.3 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
  • 2-((2r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
  • 2-((2r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
  • (2r)-2-(7-carbamoyl-1h-benzimidazol-2-yl)-2-methylpyrrolidinium
  • (2r)-2-(7-carbamoyl-1h-benzimidazol-2-yl)-2-methylpyrrolidinium
  • 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide
  • abt888
  • abt 888
  • abt-888
  • abt-888
  • abt-888
  • abt-888
  • veliparib
  • veliparib
  • veliparib
  • veliparib
  • veliparib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03400306Phase 1May 10, 2020AbbVie
NCT03581292Phase 2Nov 3, 2018National Cancer Institute (NCI)
NCT03289910Phase 2Jun 8, 2018Johns Hopkins University, National Cancer Institute (NCI)
NCT03044795Phase 2Aug 1, 2017AbbVie, Dutch Cancer Society, University of Groningen
NCT03032614Phase 2May 31, 2017University of Texas, San Antonio
NCT03061188Phase 1May 23, 2017AbbVie, Bristol-Myers Squibb, National Cancer Institute (NCI), Northwestern University
NCT03123211N/AApr 18, 2017AbbVie
NCT02985658N/ADec 5, 2016AbbVie, University of Washington
NCT02944396Phase 2Dec 1, 2016AbbVie
NCT02849496Phase 2Nov 15, 2016National Cancer Institute (NCI), Yale University
NCT03227016Phase 1Oct 31, 2016Askelios Klinik München Gauting, Central European Society for Anticancer Drug Research (CESAR)
NCT02921256Phase 2Oct 12, 2016National Cancer Institute (NCI), NRG Oncology
NCT02890355Phase 2Sep 1, 2016National Cancer Institute (NCI), Southwest Oncology Group
NCT02831179Phase 1Aug 1, 2016National Cancer Institute (NCI), Vanderbilt University
NCT02631733Phase 1Jul 15, 2016National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT02595905Phase 2Jul 7, 2016National Cancer Institute (NCI), Southwest Oncology Group
NCT02860819Phase 2Jul 1, 2016National Cancer Institute (NCI), National Cancer Institute, Slovakia
NCT02723864Phase 1Mar 22, 2016National Cancer Institute (NCI)
NCT02483104Phase 1Jul 1, 2015AbbVie
NCT02470585Phase 3Jul 1, 2015AbbVie, Australia New Zealand Gynaecological Oncology Group, Gynecologic Oncology Group
Showing 20 of 103 trials
Page 1 / 6

Organizations

Research & Development (51)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government574932006
AbbVieFor profit322742008
AbbottFor profit11322007
NRG OncologyAcademic/Hospital7022009
University of PittsburghAcademic/Hospital6012007
Johns Hopkins UniversityAcademic/Hospital5122007
Cornell UniversityAcademic/Hospital3012011
Georgetown UniversityAcademic/Hospital3312009
National Institutes of Health (NIH)Government3122006
Southwest Oncology GroupAcademic/Hospital3012011
Harvard UniversityAcademic/Hospital2122009
Mayo ClinicAcademic/Hospital2022009
Ohio State UniversityAcademic/Hospital2012009
Pediatric Brain Tumor ConsortiumAcademic/Hospital2022009
Region SyddanmarkAcademic/Hospital2212011
University of WashingtonAcademic/Hospital2222010
University of WisconsinAcademic/Hospital2022010
Yale UniversityAcademic/Hospital2022007
Yeshiva UniversityAcademic/Hospital2012010
Askelios Klinik München GautingAcademic/Hospital1012016
51 organizations
Page 1 / 3